Treatment of Latent TB Infection for Jailed Persons
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether an alternative drug, (rifampin) given
daily, is better at treating tuberculosis (TB) and more tolerable than the usual drug
treatment, isoniazid (INH). Study participants will include 972, TB infected, San Francisco
Jail inmates, aged 18 or older. One group of volunteers will take INH two times a week for 9
months, and the other group will take rifampin daily for 4 months. Medication will be
administered in jail and at the San Francisco TB Clinic if the volunteer is released from
jail prior to completing the study. Participants will be seen daily for 4 months (rifampin
group), and 2 times a week for 9 months (INH group) for directly observed therapy. Study
procedures will include 5 symptom review visits and blood samples for lab testing. Follow-up
will continue for each subject for five years after enrollment into the study.
Phase:
Phase 3
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)